ArticleScience translational medicine2022
Adenoviral-based vaccine promotes neoantigen-specific CD8
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 63 citations in OpenAlex.
- Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.Nature medicine · 2026Trial
- Colonic Polyp Regression After Nous-209 Cancer Immunotherapy: A Clinical Trial Case Report.Journal of immunotherapy and precision oncology · 2026Article
- Mutations Targeted by Nous-209 Immunotherapy Occur Early in Lynch Syndrome Carriers' Precancer Lesions with Microsatellite Instability.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- NOUS-209 Off-the-shelf Immunotherapy Has the Potential to Hit Primary and Metachronous Colorectal and Urothelial Cancers in Lynch Syndrome.Molecular cancer therapeutics · 2026Article
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1.NPJ vaccines · 2026Article
- Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy.Frontiers in immunology · 2026Review
- Stem-like T cells in cancer immunotherapy: biology, regulation and therapeutic targeting.Frontiers in immunology · 2026Review
- Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis.Signal transduction and targeted therapy · 2025Article
- Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025Review
- Neoadjuvant personalized viral vaccine prevents tumor relapse in checkpoint-resistant murine melanoma model.Journal for immunotherapy of cancer · 2025Article
- Therapeutic targeting of mismatch repair-deficient cancers.Nature reviews. Clinical oncology · 2025Review
- A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.Chinese medical journal · 2025Review
- Segmental versus Extended Resection for Colon Cancer in Lynch Syndrome.Clinics in colon and rectal surgery · 2025Review
- Anti-cancer effect of interleukin-2 fused to flagellin expressed by tumor-targeting Salmonella.Oncogene · 2025Article
- CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity.Experimental hematology & oncology · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 11 institutions in 4 countries.
Anna Morena D'AliseNouscom SRL, 00128 Rome, Italy.ORCID 0000-0002-0763-6269
Nadia BrasuArmenise-Harvard Immune Regulation Unit, Italian Institute for Genomic Medicine, 10060 Candiolo (Turin), Italy.ORCID 0000-0001-7008-3727
Carlo De IntinisArmenise-Harvard Immune Regulation Unit, Italian Institute for Genomic Medicine, 10060 Candiolo (Turin), Italy.ORCID 0000-0002-6791-7126
Guido LeoniNouscom SRL, 00128 Rome, Italy.ORCID 0000-0003-0502-1962
Valentina RussoArmenise-Harvard Immune Regulation Unit, Italian Institute for Genomic Medicine, 10060 Candiolo (Turin), Italy.
Francesca LangoneNouscom SRL, 00128 Rome, Italy.ORCID 0000-0002-3623-3004
Denis BaevArmenise-Harvard Immune Regulation Unit, Italian Institute for Genomic Medicine, 10060 Candiolo (Turin), Italy.
Elisa MicarelliNouscom SRL, 00128 Rome, Italy.ORCID 0000-0002-1180-0359
Luca PetitiArmenise-Harvard Immune Regulation Unit, Italian Institute for Genomic Medicine, 10060 Candiolo (Turin), Italy.
Simone PicelliInstitute of Molecular and Clinical Ophthalmology Basel, 4031 Basel, Switzerland.
Marwan FakihCity of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.ORCID 0000-0002-6554-5488
Dung T LeJohns Hopkins University, Baltimore, MD 21287, USA.
Michael J OvermanMD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.ORCID 0000-0001-5377-135X
Anthony F ShieldsKarmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.ORCID 0000-0002-9122-1014
Katrina S PedersenDivision of Oncology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Manish A ShahWeill Cornell Medicine, New York, NY 10021, USA.ORCID 0000-0002-6913-9655
Sarbajit MukherjeeRoswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Thea FaivreNouscom AG, 4051 Basel, Switzerland.ORCID 0000-0003-2090-2477
Patricia DelaiteNouscom AG, 4051 Basel, Switzerland.
Elisa ScarselliNouscom SRL, 00128 Rome, Italy.ORCID 0000-0002-5393-6713
Luigia PaceArmenise-Harvard Immune Regulation Unit, Italian Institute for Genomic Medicine, 10060 Candiolo (Turin), Italy.ORCID 0000-0002-1694-2401
Italian institute for Genomic Medicine · ITNouscom (Italy) · ITAllgemeine Gewerbeschule Basel · CHCity of Hope · USCornell University · USInstitute of Molecular and Clinical Ophthalmology Basel · CHJohns Hopkins University · USRoswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · USWayne State University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTranslational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI Rosalie Wollett · 1985 to 2026
$208.6MNCI NIH HHS P30 CA006973NCI NIH HHS P30 CA016672
Abstract
Upon chronic antigen exposure, CD8
Indexed as
CD8-Positive T-LymphocytesNeoplasmsAdenoviridaeAnimalsAntigens, NeoplasmHumansMiceReceptors, Antigen, T-CellAntigens, NeoplasmReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.